HPV Vaccine Adjuvant System Enhancing Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines require multiple doses and have limitations in production capacity and immunization efficiency, particularly in developing countries, where cervical cancer prevalence is high, necessitating a simplified immunization procedure and improved adjuvant system for enhanced immunogenicity.
Innovation Solution
A recombinant human papillomavirus vaccine formulation using a combined adjuvant system of aluminum adjuvant and CpG ODN, which includes VLP proteins of HPV types 16, 18, 6, 11, 31, 33, 45, 52, and 58, adsorbed onto aluminum adjuvant for stability and immunogenicity, with optimized antigen and adjuvant dosages to enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a traditional aluminum adjuvant system is used in HPV vaccines, then the vaccine provides basic immunogenicity, but the immunization procedure requires multiple doses with long intervals and the immunogenicity is insufficient
Solution Approach 1:
The patent uses a composite adjuvant system combining aluminum adjuvant (alum) with CpG ODN (oligodeoxynucleotide containing unmethylated CpG motifs). This composite approach leverages the aluminum adjuvant's ability to form depot and stimulate innate immunity while CpG ODN activates TLR9 to enhance adaptive immune response, achieving superior immunogenicity with reduced dosing frequency compared to traditional aluminum-only adjuvants
Solution Approach 2:
The patent modifies the adjuvant system by incorporating CpG ODN at optimized concentrations (5-50 μg per dose) alongside aluminum adjuvant. This parameter change in the adjuvant composition transforms the immune response profile, enabling durable protection with fewer doses by enhancing both humoral and cellular immunity through TLR9 activation
2Reliability
If the antigen dosage is increased to improve immune response, then the immunogenicity is enhanced, but the production cost and manufacturing complexity increase
Solution Approach 1:
The patent optimizes the antigen dosage to 10-100 μg per dose, which is lower than traditional HPV vaccines requiring higher doses. This parameter optimization, combined with the enhanced adjuvant system, achieves superior immunogenicity while reducing manufacturing complexity and cost by requiring less viral-like particle production
3Duration of action of stationary object
If multiple doses with long intervals are administered to achieve durable protection, then the immune response durability is improved, but the vaccination completion rate decreases due to production capacity limitations and logistical challenges
Solution Approach 1:
The patent achieves continuous durable immune protection through a simplified dosing regimen of 1-2 doses administered 0-6 months apart, eliminating the need for multiple annual boosters. The composite adjuvant system creates sustained immune memory that provides long-lasting protection, ensuring vaccination completion by reducing the number of required administrative doses
Solution Approach 2:
The optimized vaccine formulation with composite adjuvant creates preliminary strong immune memory with just 1-2 doses, establishing durable protection in advance. This preliminary action at lower dose frequency prevents the need for subsequent booster shots, improving vaccination completion rates by reducing the total number of required immunization events
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaccine composition demonstrates significantly improved immunological activity, potentially reducing the number of immunization doses, shortening intervals, and lowering antigen dosage, thereby improving immunogenicity and durability of the immune response.
Implementation Method 1
The L1 protein expressed through genetic recombination can form virus-like particles (VLPs) under particular condition
Implementation Method 2
VLPs formed by assembly of L1 of each HPV type are adsorbed onto an aluminum adjuvant
Data Source
AI summary
Disclosed in the present disclosure are a recombinant human papillomavirus vaccine composition and a use thereof. Compared with other combinations of antigens and adjuvants, the new vaccine composition provided in the present invention has a more beneficial immune effect.